Centro de Investigación Médica Aplicada-ko ikertzaileekin lankidetzan egindako argitalpenak (61)

2024

  1. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment

    Clinical and Molecular Hepatology, Vol. 30, Núm. 2, pp. 177-190

2023

  1. In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID-19 vaccine-related hepatitis

    Journal of Hepatology

  2. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma

    Cell Reports Medicine, Vol. 4, Núm. 4

  3. Transarterial Radioembolization Ought Not to Borrow Future Liver Function from Patients with Hepatocellular Carcinoma. But Does It?

    Journal of Vascular and Interventional Radiology

2022

  1. A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits

    Scientific Reports, Vol. 12, Núm. 1

  2. DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

    Cancers, Vol. 14, Núm. 9

  3. Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood

    Bioengineering and Translational Medicine, Vol. 7, Núm. 3

  4. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies

    Advances in Cancer Research (Academic Press Inc.), pp. 367-413

  5. Neoantigens as potential vaccines in hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 2

  6. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures

    Gut, Vol. 71, Núm. 6, pp. 1141-1151

2021

  1. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  2. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  3. Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis

    Gut, Vol. 70, Núm. 2, pp. 388-400

  4. Long noncoding RNA EGOT responds to stress signals to regulate cell inflammation and growth

    Journal of Immunology, Vol. 206, Núm. 8, pp. 1932-1942

  5. Long noncoding RNA NIHCOLE promotes ligation efficiency of DNA double-strand breaks in hepatocellular carcinoma

    Cancer Research, Vol. 81, Núm. 19, pp. 4910-4925

  6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9

  7. The landscape of lncrnas in hepatocellular carcinoma: A translational perspective

    Cancers, Vol. 13, Núm. 11

  8. The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation

    Nucleic Acids Research, Vol. 49, Núm. 15, pp. 8592-8609

2020

  1. Cold‐inducible rna binding protein as a vaccination platform to enhance immunotherapeutic responses against hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 11, pp. 1-18

  2. Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis

    Cancers, Vol. 12, Núm. 12, pp. 1-27